| pubmed-article:11781646 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0038250 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0278689 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0015133 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C1609982 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C1317973 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C1171411 | lld:lifeskim |
| pubmed-article:11781646 | lifeskim:mentions | umls-concept:C2003874 | lld:lifeskim |
| pubmed-article:11781646 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11781646 | pubmed:dateCreated | 2002-1-8 | lld:pubmed |
| pubmed-article:11781646 | pubmed:abstractText | This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m(2) over 96 h (days -12 to -8), etoposide 700 mg/m(2) every day x3 (days -6 to -4), and cyclophosphamide 4.2 g/m(2) on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/microl was 14 (range 10-42) and platelets <20,000/microl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal. | lld:pubmed |
| pubmed-article:11781646 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11781646 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11781646 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11781646 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11781646 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:ShibataSS | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:DoroshowJ HJH | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:MorganR JRJ | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:McNamaraMM | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:ChowWW | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:FormanSS | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:YenYY | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:MargolisPP | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:RaschkeDD | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:SomloGG | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:LongmateJJ | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:LeoneNN | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:SchriberJJ | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:VasilevSS | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:HamasakiVV | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:McGonigleKK | lld:pubmed |
| pubmed-article:11781646 | pubmed:author | pubmed-author:AlvarnasJJ | lld:pubmed |
| pubmed-article:11781646 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11781646 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:11781646 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11781646 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11781646 | pubmed:pagination | 859-63 | lld:pubmed |
| pubmed-article:11781646 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:meshHeading | pubmed-meshheading:11781646... | lld:pubmed |
| pubmed-article:11781646 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11781646 | pubmed:articleTitle | Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. | lld:pubmed |
| pubmed-article:11781646 | pubmed:affiliation | Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA. | lld:pubmed |
| pubmed-article:11781646 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11781646 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11781646 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:11781646 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
